Therapeutic antibodies that target T-cell co-inhibitory molecules display potent antitumor effects in multiple types of cancer. LSECtin is a cell surface lectin of the DC-SIGN family expressed in dendritic cells that inhibits T-cell responses. LSECtin limits T-cell activity in infectious disease, but it has not been studied in cancer. Here we report the finding that LSECtin is expressed commonly in melanomas where it blunts tumor-specific T-cell responses. When expressed in B16 melanoma cells, LSECtin promoted tumor growth, whereas its blockade slowed tumor growth in either wild-type or LSECtin-deficient mice. The tumor-promoting effects of LSECtin were abrogated in Rag1 À/À mice or in response to CD4 þ or CD8 þ T-cell depletion. Mechanistic investigations determined that LSECtin inhibited the proliferation of tumor-specific effector T cells by downregulating the cell cycle kinases CDK2, CDK4, and CDK6. Accordingly, as expressed in B16, tumor cells LSECtin inhibited tumorspecific T-cell responses relying upon proliferation in vitro and in vivo. Notably, LSECtin interacted with the coregulatory molecule LAG-3, the blockade of which restored IFNg secretion that was reduced by melanomaderived expression of LSECtin. Together, our findings reveal that common expression of LSECtin in melanoma cells engenders a mechanism of immune escape, with implications for novel immunotherapeutic combination strategies. Cancer Res; 74(13); 3418-28. Ó2014 AACR.
Introduction
Although melanoma is substantially more immunogenic than other tumors, it usually remains refractory to immunologic manipulation, despite the fact that large numbers of tumorinfiltrating lymphocytes (TIL) are often found at melanoma sites. Most patients with melanoma, even those with advancedstage disease, have circulating melanoma antigen-specific CD8 þ T cells (1) . However, these T cells are likely ineffective at inducing disease regression or preventing progression (2) . Much evidence has demonstrated that a large part of this problem is due to the immunosuppressive network at the tumor site. Despite tumor-specific CTLs and helper T cells generated, many of these effector cells are finally "turned off" at the tumor site by a number of immunosuppressive mechanisms, including tumor-induced antigen presentation impairment (3) (4) (5) , downregulation of HLA molecules (4, 6) , the elaboration of immunosuppressive factors (7) (8) (9) (10) (11) (12) (13) , as well as the influence of regulatory cell populations that may contribute to this immunosuppressive network, including regulatory T cells (Treg; refs. 14, 15) and myeloid-derived suppressor cells (MDSC; refs. 16, 17) . Recently, another immune resistance mechanism has gained much attention, specifically, the suppressive actions of coinhibitory molecules (18, 19) . Among these inhibitory receptors, monoclonal antibody targeted to CTLA4 (ipilimumab) and PD1 has demonstrated encouraging antitumor effects in initial clinical trials (20, 21) . Accumulating studies have implied that combinatorial modulation is more effective (22) . In one study, vaccine-treated mice were found to have significantly higher overall survival rates if they were also treated with antibodies against PD1 and CTLA4 (23). Thus, the identification of novel inhibitory receptors in antitumor immune responses is important to the development of more effective combinatorial strategies.
The role of lectin in pathogen detection has been extensively appreciated (24) , but our awareness of lectin in immune homeostatic control is relatively new. A few studies have reported inhibitory control mechanisms that act on effector T cells in the context of antitumor immunity. For example, Tim-3/galectin-9 (Gal-9) pathway modulation affects tumor growth (25) ; LSECtin, which belongs to the C-type lectin receptor superfamily, is a type II transmembrane protein that is highly expressed in the liver (26) . Our previous studies revealed that LSECtin, when expressed in the liver, acted as a co-inhibitory molecule and limited the ability of T-cell immunity to promote HBV tolerance (27, 28) . Immunologically, tumors are quite similar to chronic viral infections. Because the potential role of LSECtin in antitumor immunity remains unknown, we hypothesized that tumor cells might hamper antitumor T-cell immune responses through LSECtin and that this mechanism might help to shift the balance toward an immunosuppressive environment at the tumor site. In this study, we found that LSECtin expression was detected in human melanoma tissues and induced on melanoma cells within a tumor microenvironment. Both in vivo and in vitro evidence was provided for the relevance of LSECtin-mediated immunosuppression as a novel mechanism exploited by tumor cells to facilitate host immune system escape.
Materials and Methods

Cell lines, animals, and reagents
The B16 cell line was obtained from National Platform of Experimental Cell Resources for Sci-Tech and cultured in DMEM supplemented with 10% heat-inactivated FBS and 100 U/mL penicillin. To guarantee cell line authenticity, cell line was aliquoted and banked, and cultures were grown and used for a limited number of passages before starting a new culture from stock. Cell lines were routinely tested for mycoplasma contamination. C57BL/6 female mice were used at the age of 6 to 8 weeks and purchased from Beijing HFK Bioscience Company and maintained in a specific pathogen-free facility. LSECtin KO mice are described (26) . RAG1 KO mice were obtained from Model Animal Research Center (Nanjing, China). Information of cytokines and antibodies is available in Supplementary Methods.
Patients
We studied previously untreated patients with melanoma at Beijing Cancer Hospital (Beijing, China). Patients gave written, informed consent and the study was approved by the Ethics Committee of Beijing Cancer Hospital. Clinical characteristics related to samples from 3 patients with melanoma are shown in Supplementary Table S4 .
Isolation of melanoma cell and TILs
Melanoma tissues were dissociated by finely mincing in complete medium followed by collagenase (Type I, Sigma) and DNase (Roche) digestion for 1 hour. The cell suspension was centrifuged on a discontinuous density gradient to remove tumor fragments, dead cells, and red blood cells. Tumor cells or TILs were collected and washed thoroughly for flow cytometry. Details can be found in Supplementary Methods.
FACS reagents and staining
Information of antibodies used in FACS is available in Supplementary Methods. LSECtin monoclonal antibody (CCB059) was used as described previously (26) . IFNg patients cellular staining was performed according to the protocol provided by the manufacturers (eBioscience). Cells were analyzed using the FACSCalibur flow cytometer with data analyzed by FlowJo software (Treestar).
Quantitative real-time PCR
Human tumor quantitative PCR tissue arrays were purchased from OriGene. Cancer survey array (CSRT104) contained 7 types of different cancers. Melanoma-specific array (MERT101) contained 40 melanoma samples. All relevant clinical information can be found in Supplementary Material or on the OriGene website. Detailed protocol and primers can be found in Supplementary Methods.
Immunohistochemistry
Melanoma and normal tissue microarray (TMA) sections with stage and grade information (ME481a) were bought from US Biomax. All relevant clinical information can be found in Supplementary Material or on the US Biomax website. Detailed protocols can be found in Supplementary Methods. In vitro induction of B16-specific T cells and functional assays Splenocytes from vaccinated mice were obtained and cultured with 10 mg/mL TRP2 180-188 peptide and 10 ng/mL IL2. After 5 days, B16-specific CD4 þ or CD8 þ T cells were obtained from these splenocytes by FACS for further coculture assays. Protocols of T-cell proliferation, cell cycle, and apoptosis can be found in Supplementary Methods.
ELISPOT and ELISA Lymph node cells or splenocytes were harvested from vaccinated mice and subjected to ELISPOT analysis. Detailed protocols can be found in Supplementary Methods. Lymph node cells or B16-specific CD4 þ or CD8 þ T cells were restimulated ex vivo with irradiated B16-LSECtin and B16-mock cells for 48 hours. Cell-free supernatants were collected and subjected to cytokine determination.
LAG-3 interaction and blockade
Protocols of SPR and protein ELISA can be found in Supplementary Methods. Anti-LAG-3 (C9B7W) was used to block interaction between LAG-3 and LSECtin. Details can be found in Supplementary Methods.
Statistical analyses
The statistical differences between different groups were determined by the Student t test or 2-way ANOVA test in GraphPad Prism software. All results shown in the manuscript are representative of at least 2 independent experiments with similar results.
Results
LSECtin is expressed by human and murine melanoma tissues
LSECtin is a type II transmembrane protein that was initially found to be expressed in the liver. To determine whether LSECtin was expressed in human tumors, we performed real-time PCR (RT-PCR) with human tumor tissue cDNA (Fig.  1A) . We detected increased expression of LSECtin in primary bladder (2 of 10), Crohn's (0 of 10), endometrial (8 of 10), gastroesophageal (1 of 11), melanoma (3 of 11), pancreatic (1 of 10), and sarcoma (4 of 10) tumor samples compared with average level of normal skin tissues. Melanoma, bladder, and pancreatic cancers had a higher LSECtin expression among these 7 types of tested tumors. Our previous studies indicated that LSECtin was a negative regulator of T-cell immune responses. Melanoma is a well-studied tumor type that shows a T-cell-inflamed phenotype consisting of infiltrating T cells. Therefore, we chose to determine whether LSECtin could play a role in anti-melanoma immunity. In addition, 20 of 40 human melanoma samples showed obvious LSECtin expression (Fig.  1B ). An immunohistochemistry analysis also detected LSECtin expression in 20 of 32 melanoma samples. We found LSECtin immunoreactivity in the plasma membrane (Fig. 1C) , cytoplasm, or both. Fresh isolated melanoma cells from patients expressed cell surface LSECtin protein (Fig. 1D ). Previous studies showed that the B16 murine melanoma cell line on the C57BL/6 mouse strain background is a well-studied model of human melanoma (29); we next determined whether the B16 cells also expressed LSECtin. First, we analyzed LSECtin mRNA level in B16 cells and found that the band of LSECtin was feeble. This suggested that LSECtin expression in B16 cells was not constitutive and could possibly be induced in vivo. To test this, B16 cells and tumor cells extracted from B16-inoculated mice were obtained to analyze LSECtin expression. We found that tumor cells had a significantly higher induction of LSECtin expression at both mRNA and protein levels compared with B16 cells (Supplementary Fig. S1A and S1B).
Because LSECtin expression was induced in B16 cells, we hypothesized that intratumoral factors may stimulate LSECtin expression on B16 cells. When treated with tumor extract solution from fresh tumors, B16 cells were induced to express LSECtin ( Fig. 2A and B) . Addition of a neutralizing monoclonal antibody against IL6 or IL10 significantly blocked tumor extract solution-mediated LSECtin upregulation (Fig. 2C) , suggesting that intratumoral IL6 and IL10 could stimulate LSECtin expression. In support, IL6 and IL10 proteins were detected in the tumor extract solution ( Supplementary Fig. S2 ). Furthermore, when treated with recombinant IL6 and IL10, B16 cells were also induced to express LSECtin ( Fig. 2D and E) . Taken together, we determined that LSECtin was expressed in human melanoma tissues, and its expression could be induced in B16 cells within tumor microenvironment.
Tumor-derived LSECtin promotes B16 melanoma progression
Because LSECtin was not constitutively expressed by B16 cells, we obtained a stable transfectant B16-LSECtin (Supplementary Fig. S3 ) to study the role of tumor-derived LSECtin. First, all stable transfectants exhibited similar growth rates (Fig. 3A) , indicating that B16-LSECtin cells had no growth advantage over B16-mock cells. Remarkably, B16-LSECtin cell administration resulted in a more rapid melanoma growth in both wild-type (WT) and LSECtin KO mice ( Fig. 3B and C ; ref. 27) . This indicated that tumor-derived LSECtin could promote B16 melanoma progression in mice. Furthermore, we explored the impact of LSECtin blockade on B16 melanoma progression by injecting C57BL/6 mice with LSECtin antibody (Supplementary Fig. S4 ) to investigate whether tumor cells could overwhelm antitumor cell responses in vivo through LSECtin-dependent mechanisms. WT C57BL/6 mice were inoculated with B16 (Fig. 3D ) or B16-LSECtin ( Supplementary  Fig. S5 ) cells and treated with anti-LSECtin or control antibody. We found that anti-LSECtin significantly prevented B16 tumor progression. Furthermore, LSECtin KO mice were used to exclude the potential cross-reactivity of anti-LSECtin against host cell-expressed LSECtin. We found that anti-LSECtin could delay the progression of B16 melanoma in the absence of host LSECtin (Fig. 3E) . Collectively, our results demonstrated that tumor-derived LSECtin actually promotes B16 tumor growth in vivo.
LSECtin, when expressed by B16 cells, reduces the number of tumor-infiltrating effector T cells
To determine which mechanisms are involved in LSECtinmediated tumor promotion, tumor tissue histology was assessed. Ki67 was used to detect tumor cell proliferation (30) . There was no difference in cell proliferation between the two groups, indicating that, in this model, tumor cell growth arrest was not a main component of tumor control (Fig. 4A) . To determine whether apoptosis could contribute to tumor promotion in our model, a terminal-deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay was performed. Only marginal apoptosis and no difference was observed between the two groups (Fig. 4B) . Furthermore, to determine whether immune cells, particularly T and B cells, were involved in LSECtin-mediated tumor promotion, we inoculated Rag1 À/À (31) and WT mice with B16-LSECtin and B16-mock cells. Interestingly, LSECtin had no effect on B16 melanoma growth promotion when T and B cells were absent (Fig. 4C ). Because LSECtin was previously shown to dampen Tcell-mediated antiviral immune responses (28), we first hypothesized that tumor-derived LSECtin could promote B16 melanoma growth by inhibiting T-cell-mediated antitumor immunity. To test this, we depleted CD4 þ and CD8 þ T cells in mice before treatment. As expected, the LSECtinmediated melanoma promotion was abrogated in response to the depletion of both CD4 þ and CD8 þ T cells (Fig. 4D) . Taken together, these data imply that LSECtin-mediated melanoma promotion was mainly due to weakened antitumor T-cell immunity.
To assess the impact of LSECtin on antitumor T-cell immune responses, we first isolated tumors and assayed them for T-cell infiltration using flow cytometry. Consistently, B16-LSECtin cell inoculation resulted in tumor growth promotion, and the tumor weights were significantly higher in mice inoculated with B16-LSECtin cells (Fig. 5A) ; this difference also corresponded to a decrease in the absolute number of CD3 þ T cells (Fig. 5B ). In addition, the absolute number of CD8 þ T cells/ gram tumor (Fig. 5C ) decreased significantly by approximately 3-fold in B16-LSECtin mice, compared with B16-mock mice. Moreover, the absolute number of CD4 þ T cells (Fig. 5D ) also decreased, but it was not statistically significant. Because tumor-derived LSECtin reduced the number of tumor-infiltrating T cells, we next examined the impact of LSECtin on the proliferation of tumor-infiltrating T cell. B16-specific CD4 þ and CD8 þ T cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) and cocultured with irradiated B16-LSECtin and B16-mock cells in the presence of coated anti-CD3 and soluble IL2. The CFSE dilution assay results (Fig. 5E ) demonstrated that B16-expressed LSECtin could significantly inhibit the proliferation of B16-specific CD8 þ T cells, but did not have such an obvious effect on B16-specific CD4 þ T cells. We also quantified the expression of key genes that control the cell cycle. In agreement with the above CFSE dilution analysis, we found that the expression level of the cyclin-dependent kinase inhibitor p21 was increased and those of the G 1 -S phase-associated genes CDK2, CDK4, and CDK6 were decreased in CD8 þ T cells that were cocultured with B16-LSECtin versus those cocultured with B16-mock cells (Fig. 5F ), suggesting that CD8 þ T cells cocultured with B16-LSECtin cells failed to enter cell cycle. There was no difference in the expression of another inhibitor p27 between these two groups (Fig. 5F ). It indicated that p21 might be a key factor in LSECtin-mediated T-cell proliferation. Because tumor-specific T cells are more prone to apoptosis in the tumor microenvironment (32, 33), we next investigated whether LSECtin could affect the apoptosis of B16-specific T cells. B16-specific CD4 þ and CD8 þ T cells were cocultured with B16-LSECtin and B16-mock cells, and the percentages of Annexin V þ T cells were analyzed at the indicated time points.
We found that B16-expressed LSECtin did not affect the apoptosis of either B16-specific CD4 þ or CD8 þ T cells in vitro (Fig. 5G) . Taken together, B16-expressed LSECtin inhibits the proliferation and reduces the numbers of tumor-infiltrating B16-specific effector T cells.
LSECtin, when expressed by B16 cells, inhibits tumorspecific T-cell immune responses in vivo and in vitro
The immunoregulatory effect of LSECtin and its ability to promote B16 melanoma growth in mice prompted us to investigate whether LSECtin could inhibit tumor-specific immune responses in the tumor microenvironment. Tumordraining lymph nodes (TDLN) were harvested from mice that had been inoculated with B16-LSECtin or B16-mock cells. Lymph node cells were examined for antigen-specific IFNg production using intracellular staining (Fig. 6B) and an ELI-SPOT assay (Fig. 6C) following TRP2 180-188 stimulation for 6 and 24 hours, respectively. We found that CD8 þ T cells from mice inoculated with B16-LSECtin cells secreted lower amounts of IFNg than did control mice. Because LSECtin could inhibit the tumor-specific T-cell immune responses in the TDLNs, we next investigated whether B16-expressed LSECtin could also inhibit peripheral antitumor immune responses. B16-LSECtin and B16-mock cells were subcutaneously injected into C57BL/6 mice. We then performed ELISPOT assays to detect TRP2-specific, IFNg-producing CD8 þ T cells in splenocytes isolated from these mice. Substantially lower levels of TRP2-specific IFNg production were observed in splenocytes from mice injected with B16-LSECtin cells (Fig. 6D) . Collectively, we demonstrated that LSECtin-expressing B16 cells could inhibit the effector functions of B16-specific T cells, both in the TDLNs and the periphery. Next, WT C57BL/6 mice were implanted with irradiated B16 cells, after which the lymph node cells were isolated and then restimulated ex vivo with irradiated B16-LSECtin and B16-mock cells. IFNg ELISA showed results consistent with the intracellular IFNg staining. TDLN cells that were cocultured with B16-LSECtin cells produced significantly lower levels of IFNg (Fig. 6F) . Similarly, we obtained B16-specific CD8 þ T cells, as described above, and cocultured these cells with irradiated B16-LSECtin and B16-mock cells. Consistently, CD8 þ T cells cocultured with B16-LSECtin cells also secreted smaller amounts of IFNg (Fig. 6F) . Furthermore, we obtained B16-specific effector CD4 þ T cells (CD4 þ CD25 À ) and Treg-enriched
) and cocultured them with irradiated B16-LSECtin and B16-mock cells in the presence of coated anti-CD3. We found that LSECtin-expressing B16 cells could inhibit IFNg secretion from effector CD4 þ T cells (Fig. 6G ) and induce more IL10 production from Treg cells (Fig. 6G) . Collectively, B16-expressed LSECtin inhibits the generation of tumor-specific T-cell immune responses both in vivo and in vitro.
LSECtin interacts with LAG-3 to inhibit IFNg secretion of effector T cells
Because LSECtin is a transmembrane protein with an obvious role as a regulator of T-cell immune responses, studies that aim to identify the binding partner for LSECtin are warranted. Because of its co-inhibitory function, we used the bioinformatics tool PRINCESS (34) to screen for LSECtin's interacting partner among some known co-inhibitory molecules reported by a series of literature. Among these candidates, LAG-3 obtained the highest score. Interestingly, LAG-3 was previously thought to contribute to tumor-mediated immunosuppression (35) (36) (37) . Preclinical studies that used a LAG-3 blocking antibody for cancer treatment revealed enhanced activation of antigen-specific T cells at the tumor site and disruption of tumor growth (38) . To determine whether LSECtin could interact with LAG-3, we first performed surface plasmon resonance (SPR) to determine the interactions between LSECtin and LAG-3, BTLA (another candidate with the highest score) or LSECtin itself, using a monoclonal antibody as a positive control. We immobilized these candidate proteins and injected LSECtin at a concentration of 500 ng/mL. Among the tested candidates, LAG-3 (Fig. 7A) showed obvious binding to LSECtin with a relative affinity (Fig. 7B) slightly lower than that of LSECtin itself and monoclonal antibody against LSECtin, whereas the other candidate BTLA did not bind. Next, a fusion protein-binding ELISA was performed to confirm the interaction between LSECtin and LAG-3. We coated the plate with LAG-3 and BTLA (1 mg/mL) and incubated the plate with LSECtin at various concentrations. The results revealed that LSECtin bound to LAG-3 in a dosedependent way (Fig. 7C) . In addition, a co-immunoprecipitation assay was used to further verify the interaction between LSECtin and LAG-3 (Fig. 7D) . Finally, we performed a cell surface staining assay to further determine whether LSECtin could bind to LAG-3 on the surface of live cells. We found that LSECtin could bind to 293T cells that had been transiently transfected with LAG-3 (Fig. 7E) .
We used in vitro T-cell activation assays to investigate the functional significance of the LSECtin/LAG-3 interaction. LSECtin or control IgG was coated onto plates, and T cells sorted from WT C57BL/6 mice were cultured with or without LAG-3 blocking antibodies (C9B7W) in the presence of coated anti-CD3 and soluble anti-CD28. The expression of LAG-3 on T cells was confirmed by flow cytometry (Supplementary Fig. S7 ). As expected, LSECtin dramatically inhibited IFNg secretion from the T cells, which was consistent with our observations regarding antitumor T-cell immune responses. In addition, LAG-3 blocking antibodies partially restored IFNg secretion (Fig. 7F) . To understand the functional significance of the LSECtin/LAG-3 interaction in antitumor immunity, we Individual samples are represented as dots, and bars represent mean. E, B16-specific CD4 þ and CD8 þ T cells were labeled with CFSE and then cocultured with irradiated B16-LSECtin or B16-mock cells at a ratio of 5:1 in the presence of plate-bound anti-CD3 and soluble IL2. CFSE dilution was analyzed after 48 hours. Graphs are representative of three independent experiments. F, cell-cycle-associated gene expression in B16-specific CD8 þ T cells co-cultured with B16-LSECtin (black) or B16-mock (gray) cells was determined using RT-PCR and Western blotting. Ã , P < 0.05. Data represent the mean AE SEM of two different experiments. G, B16-specific CD4 þ and CD8 þ T cells were cocultured with B16-LSECtin and B16-mock cells. T cells were harvested at the indicated time points, and the percentages of Annexin V þ in the CD4 þ and CD8 þ T cells were analyzed using flow cytometry. (Fig. 7G) . In summary, LSECtin interacted with LAG-3 to inhibit IFNg secretion from effector T cells during antitumor immune responses.
Discussion
The data presented herein demonstrate that tumors can overwhelm effector T-cell immune responses via LSECtinmediated mechanisms. We found LSECtin was expressed by human melanoma and induced to be expressed by B16 cells in response to tumor microenvironmental stimuli. Using a combination of in vivo and in vitro experiments, we have revealed a link between LSECtin-mediated immunoregulation and its contribution to tumor immune escape. LSECtin expression resulted in enhanced B16 tumor growth and inhibited the generation of tumor-specific T-cell immune responses. Moreover, blockade of the inhibitory effects of LSECtin resulted in a reduced tumor mass.
Tumor cells can grow unfettered by escaping host immune system surveillance, which is progressively suppressed as a result of tumor progression and metastasis. Many immunosuppressive strategies can be used by tumor cells to disrupt the immune system. In previous years, the suppressive actions of co-inhibitory molecules have gained considerable attention. Tumor cells can evade immune control by upregulating various co-inhibitory ligands, thereby limiting the therapeutic potential of current anticancer immunotherapies. Herein, we first reported that LSECtin is expressed on melanoma cells and is used by tumor cells to damper T-cell antitumor immune responses. Previous studies revealed that LSECtin was also expressed on other immune cells, including macrophages and monocyte-derived dendritic cells (MDDC; ref. 39). We used LSECtin-deficient C57BL/6 mice to develop a B16 melanoma model and found that tumor-derived LSECtin could promote melanoma growth in the absence of host LSECtin. Meanwhile, the role of LSECtin expression on immune cells in antitumor immunity should be investigated in the future.
To decipher the underlying mechanism by which tumorderived LSECtin inhibited tumor-specific T-cell immune responses, we sought to identify the binding partner of LSECtin on the T-cell surface. Combing with an informatics tool and literature mining, we identified the lymphocyte activation gene-3 (LAG-3) as a putative receptor of LSECtin on the Tcell surface. Previous studies revealed that LAG-3 could inhibit þ T cells (right) were subjected to restimulation ex vivo with irradiated B16-LSECtin (black) and B16-mock (gray) cells. Ã , P < 0.05;
, sorted from restimulated splenocytes, were also subjected to restimulation ex vivo with irradiated B16-LSECtin (black) and B16-mock (gray) cells in the presence of 2 mg/mL coated anti-CD3. ÃÃ , P < 0.01. These results are representative of three independent experiments. the infiltration and expansion of both CD4 þ and CD8 þ T cells (40) . Like other co-inhibitory molecules, LAG-3 was also used by tumors to disrupt antitumor T-cell immune responses (35, 36, 38) . In addition, LAG-3 protects A375 melanoma cells from Fas-mediated apoptosis through its ligand MHC II signaling capacity in melanoma cells (37) . Herein, we found that the inhibitory role of LSECtin in B16 immunity was significantly similar to that of LAG-3 and identified for the first time that LSECtin, expressed on the surface of B16 melanoma cells, was another putative ligand for LAG-3. Functionally, antibody blockade of LAG-3 restored the reduced IFNg secretion mediated by both recombinant and tumor-expressed LSECtin. Taken together, in contrast to the apoptosis resistance mediated by the MHC II/LAG-3 axis, we found that LSECtin could interact with LAG-3 to damper antitumor immunity by inhibiting IFNg secretion from antigen-specific effector T cells.
Immunotherapy for cancer has now become one of the most successful strategies for the treatment of patients with tumors. This cancer treatment strategy aims to turn on co-stimulators and/or turn off co-inhibitors of T-cell immunity. Interventions that would enhance tumor-specific immunity by modulating co-inhibitors have demonstrated some clinical successes. For example, the anti-CTLA4 and anti-PD1 monoclonal antibodies showed promising antitumor activity against various types of tumors in clinical trials (20) (21) (22) . However, preclinical studies have indicated that blockade of the ligands of these co-inhibitors, which are expressed on various tumor cells, like PD-L1, also delivered promising clinical impacts. In a phase I trial, the anti-PD-L1 antibody BMS-936559 showed modest antitumor activity in patients with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma (41) . Our preliminary blocking experiment also showed that the administration Figure 7 . LSECtin interacts with LAG-3 to inhibit IFNg secretion from effector T cells. A, an SPR analysis of the binding of 500 ng/mL injected LSECtin to 500 ng/mL immobilized LAG-3, BTLA, recombinant LSECtin, and LSECtin mAb on a sensor chip. B, the specificity and affinity were determined using SPR analysis. Various concentrations of LAG-3 or LSECtin mAb were flowed over 500 ng/mL of immobilized LSECtin on a sensor chip. The Kd values for LAG-3/ LSECtin and LSECtin mAb/LSECtin were 5.65 and 2.46 mmol/L, respectively. SPR data are presented as signals (a.u.) over time (seconds). Data are representative of three independent experiments. C, ELISA plates were coated with 1 mg/mL of LAG-3 or BTLA and then incubated with LSECtin at various concentrations. D, confirmation of the LAG-3/LSECtin interaction via coimmunoprecipitation (IP) assays. IB, immunoblotting. E, HEK293T cells that had been transfected with LAG-3 or control plasmid were stained with an LSECtin (solid line) or control IgG (shaded). F, plates were coated with 5 mg/mL of anti-CD3 and 10 mg/mL of LSECtin or control IgG. Sorted T cells from WT C57BL/6 mice were cultured with 2 mg/mL of soluble anti-CD28 and 50 mg/mL of anti-LAG-3 (C9B7W) or isotype control. ÃÃÃ , P < 0.001. Data are representative of three independent experiments. G, plates were coated with 2 mg/mL of anti-CD3. B16-specific T cells, obtained from immunized mice as described, were cocultured with irradiated B16-LSECtin (black) and B16-mock (gray) cells in the presence of 50 mg/mL of anti-LAG-3 (C9B7W) or isotype control. Ã , P < 0.05. Data are representative of two independent experiments.
of LSECtin polyclonal antibody could slow melanoma progression in mice. In the future, a specific monoclonal LSECtinblocking antibody should be developed, and details of the immune responses after the administration of this blocking antibody should be further evaluated. Meanwhile, accumulating evidence suggests that optimizing immunotherapy requires treatments that affect multiple facets of the immune response. In a phase I trial, deeper and more rapid clinical antitumor responses were observed in patients with advanced melanoma who were treated with the combination therapy of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1; ref. 22 ).
The suppressive role of LSECtin in antitumor immunity, presented herein, will provide a foundation for potential combinatorial immunotherapy strategies in combination with the blockade of other co-inhibitory molecules.
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